This community webinar, hosted by FAST and the Angelman Syndrome Association (ASA), features representatives from Ionis and Ultragenyx discussing Phase 3 clinical trials in Europe and the UK.

Topics include:

Leave a Reply

Your email address will not be published. Required fields are marked *